Merck, Incyte chalk up promising melanoma data for Keytruda-epacadostat combo
admin 9th September 2017 Uncategorised 0The true test of a new Keytruda combination—with Incyte’s IDO1 inhibitor epacadostat—won’t deliver results till early next year. But in the meantime, Merck & Co. and Incyte unveiled some hotly anticipated data from a small, earlier-stage trial of the pairing.
More: Merck, Incyte chalk up promising melanoma data for Keytruda-epacadostat combo
Source: fierce